A 2004 proof-of-idea trial in Mozambique discovered that the vaccine reduced serious malaria by 58 % in children ages one to four. The brand new trials shall include studies to assess this promising vaccine candidate in younger age ranges including infants, the groupings that suffer most from malaria and that would benefit the many from an effective vaccine against the condition. Malaria takes the lives greater than one million people every year, most of them small children under five years old. We should have new equipment to fight this deadly disease, said Dr.The company announced that Amy Belt, Director of Covidien Ventures, has joined AEGEA’s Table of Directors. ‘Capital elevated will allow us to total our product development effort and begin the next stage of medical testing of our fresh global endometrial ablation program to treat abnormal uterine bleeding,’ commented Don Gurskis, General Supervisor of AEGEA. ‘We are pleased with our clinical leads to date and look forward to providing an improved option.’ Irregular uterine bleeding impacts one in four women of reproductive age group and represents one of the largest and fastest developing commercial opportunities in the women’s wellness market.